Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Bupropion ameliorates methamphetamine dependence in some patients

Dec. 28, 2007

Catalyst reports positive phase II trial results for vigabatrin for cocaine addiction

Dec. 11, 2007

HDAC5 function in nucleus accumbens altered by chronic cocaine and stress

Dec. 5, 2007

Low daily doses of rimonabant reduce responses to cannabis

Nov. 30, 2007

E.U. approves Merck Serono's Cyanokit for cyanide poisoning

Nov. 29, 2007

Tiagabine ineffective in cocaine dependence study

Nov. 22, 2007

DOR BioPharma enters cooperative agreement for RiVax with Walter Reed Army Institute

Nov. 21, 2007

Acrux initiates production of Nicotine MDTS following successful phase I clinical trial

Nov. 16, 2007

Aeolus's AEOL-10150 demonstrates protection against mustard gas

Nov. 12, 2007

Celtic Pharma completes enrollment in phase IIb TA-NIC study

Nov. 6, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...